Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$311.41 USD

311.41
1,631,199

+2.96 (0.96%)

Updated May 14, 2024 04:00 PM ET

After-Market: $311.50 +0.09 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.

Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.

    Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

    Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

      Amgen Looking to Broaden Leukemia Drug Blincyto's Label

      Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.

        Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak

        Regeneron Pharmaceuticals, Inc. (REGN) reported disappointing results for the fourth quarter of 2016. The outlook for 2017 did not give investors anything to cheer for either.

          Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

          Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.

            Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?

            Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release fourth-quarter 2016 results on Feb 9, before the opening bell.

              Kinjel Shah headshot

              Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat

              Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.

                Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.

                Amgen Inc. (AMGN) announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

                  Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

                    Merck???s Keytruda Gets Priority Review for Bladder Cancer

                    Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.

                      Are Options Traders Betting on a Big Move in Amgen (AMGN) Stock?

                      Investors in Amgen Inc. (AMGN) need to pay close attention to the stock based on moves in the options market lately.

                        Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study

                        Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .

                          Arpita Dutt headshot

                          Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data

                          Major highlights this week were earnings results from companies like Celgene (CELG) and pipeline updates.

                            Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?

                            Mallinckrodt plc (MNK) is set to report results for the quarter ended Dec. 30, 2016 on Feb 7.

                              The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

                              The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

                                Should You Sell Amgen (AMGN) Before Earnings?

                                Amgen (AMGN) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.

                                  Merck Keytruda Gets EU Approval for First-Line Lung Cancer

                                  Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy Keytruda has been approved by the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer.

                                    Madeleine Johnson headshot

                                    Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting

                                    Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.

                                      Kinjel Shah headshot

                                      Pfizer (PFE) Q4 Earnings Lag, Sales Top; '17 Sales View Soft

                                      Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.

                                        Arpita Dutt headshot

                                        4 FDA Decisions to Watch Out for in Feb 2017

                                        So far this year, the FDA has approved one drug. Will the pace of drug approvals pick up in February?

                                          Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug

                                          Pfizer Inc. (PFE) announced that Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company's marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz.

                                            Amgen Wins Favorable CHMP Opinion for Humira Biosimilar

                                            Amgen (AMGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on the company's marketing authorization application (MAA) for ABP 501.

                                              Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?

                                              We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.

                                                Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft

                                                Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.

                                                  Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon

                                                  Novartis' (NVS) fourth-quarter 2016 results were mixed with the company beating earnings estimates but missing on revenues. The company has been facing challenging conditions for the past few quarters.